Plasmodium falciparum chloroquine resistance is a major cause of worldwide increases in malaria mortality and morbidity. Recent laboratory and clinical studies have associated chloroquine resistance with point mutations in the gene pfcrt. However, direct proof of a causal relationship has remained elusive and most models have posited a multigenic basis of resistance. Here, we provide conclusive evidence that mutant haplotypes of the pfcrt gene product of Asian, African, or South American origin confer chloroquine resistance with characteristic verapamil reversibility and reduced chloroquine accumulation. pfcrt mutations increased susceptibility to artemisinin and quinine and minimally affected amodiaquine activity; hence, these antimalarials warrant further investigation as agents to control chloroquine-resistant falciparum malaria.
Chloroquine has for decades been the primary chemotherapeutic means of malaria treatment and control (1) . This safe and inexpensive 4-aminoquinoline compound accumulates inside the digestive vacuole of the infected red blood cell, where it is believed to form complexes with toxic heme moieties and interfere with detoxification mechanisms that include heme sequestration into an inert pigment called hemozoin (2) (3) (4) . Chloroquine resistance (CQR) was first reported in Southeast Asia and South America and has now spread to the vast majority of malaria-endemic countries (1) . pfcrt was recently identified as a candidate gene for CQR after the analysis of a genetic cross between a chloroquine-resistant clone (Dd2, Indochina) and a chloroquine-sensitive clone (HB3, Honduras) (5-7). The PfCRT protein localizes to the digestive vacuole membrane and contains 10 putative transmembrane domains (7, 8) . Point mutations in PfCRT, including the Lys 76 3 Thr (K76T) mutation in the first predicted transmembrane domain, show an association with CQR in field isolates and clinical studies (7, 9, 10) . Episomal complementation assays demonstrated a lowlevel, atypical CQR phenotype in chloroquine-selected, transformed, pseudo-diploid parasite lines that coexpressed the Dd2 form of pfcrt (containing eight point mutations; Table 1 ), under the control of a heterologous promoter, with the wild-type endogenous allele (7) .
To address whether mutations in pfcrt are sufficient to confer CQR, we implemented an allelic exchange approach to replace the endogenous pfcrt allele of a chloroquine-sensitive line (GC03) with pfcrt alleles from chloroquine-resistant lines of Asian, African, or South American origin (Table 1 ) ( fig. S1 ) (11) . This approach maintained the endogenous promoter and terminator regulatory elements for correct stage-specific expression and did not use chloroquine during the selection procedure. As a result of this gene's highly interrupted nature (13 exons) and the dissemination of point mutations throughout the coding sequence, two rounds of genetic transformation were required. This enabled us to obtain pfcrt-modified clones that expressed the pfcrt allele from the chloroquineresistant lines Dd2 (clones C3 Dd2 and C4 Dd2 ), K76I (C5 K76I ), and 7G8 (C6 7G8 ). We also obtained the C2 GC03 clone in which recombination had occurred downstream of the functional allele, providing a critical control in correcting for any influence of inserting the two selectable marker cassettes without exchanging pfcrt point mutations (Table 1) ( fig. S1 ).
pfcrt allelic exchange was confirmed by Southern hybridization and polymerase chain reaction (PCR) analysis ( fig. S2 , A to D, and table S1). Reverse-transcription PCR analysis confirmed transcription of the recombinant functional pfcrt allele ( fig. S2C ), whereas no transcription was observed from the downstream remnant pfcrt sequences that lacked a promoter and 5Ј coding sequence. Western blot analysis (7, 8) Phenotypic analysis showed that mutant pfcrt alleles conferred a CQR phenotype to chloroquine-sensitive P. falciparum (Fig.  1A) . Recombinant clones expressing pfcrt alleles from the chloroquine-resistant lines Dd2, K76I, and 7G8 all had 50% inhibitory concentration (IC 50 ) values in the range of 100 to 150 nM. These IC 50 values were typically 70 to 90% of those observed with the nontransformed chloroquine-resistant lines. All these lines equaled or exceeded the 80 to 100 nM level previously proposed as a threshold diagnostic of in vivo resistant infections (12, 13) . In comparison, chloroquine IC 50 values in the recombinant control lines C1 GC03 and C2 GC03 were comparable to those observed with the initial GC03 line (20 to 30 nM). Acquisition of resistance was even more pronounced for the active metabolite monodesethylchloroquine, with IC 50 values in the range of 600 to 1200 nM for the pfcrt-modified lines, versus 35 to 40 nM for chloroquine-sensitive lines (table S2) .
The lower chloroquine IC 50 values observed in the pfcrt-modified clones, relative to the nontransformed chloroquine-resistant lines, may be a consequence of the reduced PfCRT expression levels and other effects stemming from the complex genetic locus created in these recombinant clones ( fig. S1 ). Alternatively, additional genetic factors might be required to attain high chloroquine IC 50 values. One candidate secondary determinant is pfmdr1, which encodes the P-glycoprotein homolog Pgh-1 that localizes to the digestive vacuole (14 -16) . Reed et al. (17) recently demonstrated by allelic exchange that removal of three pfmdr1 point mutations (1034C, 1042D, and 1246Y) from the 7G8 line decreased the chloroquine IC 50 values; however, introduction of these mutations into endogenous pfmdr1 did not alter the susceptible phenotype of a chloroquine-sensitive line. Our experiments were performed with the GC03 clone, which carries the HB3-type pfmdr1 allele that in two P. falciparum genetic crosses showed no association with decreased chloroquine susceptibility (5, 18) . This allele contains the 1042D point mutation that is prevalent in chloroquine-resistant South American isolates, although this mutation does not show a consistent association with CQR in isolates from other malariaendemic regions (6, 19 -21) .
Acquisition of elevated chloroquine IC 50 values in the pfcrt-modified clones was accompanied by verapamil chemosensitization, a hallmark of the CQR phenotype (Fig. 1A ) (22) . Association of both parameters with pfcrt represents a marked departure from earlier suppositions that verapamil reversibility of P. falciparum CQR was analogous to this compound's chemosensitization of multidrug resistance in mammalian tumor cells, believed to be mediated primarily by adenosine triphosphate-dependent P-glycoproteins (22 , and 7G8 clones as compared with the chloroquinesensitive clones GC03 and C2 GC03 (Fig. 1G ). These assays measured the uptake into infected red blood cells of the saturable component of chloroquine at nanomolar concentrations, a measure that has been previously found to clearly distinguish chloroquine-resistant and chloroquine-sensitive parasites (24, 25) .
Having this set of clones on the same genetic background, in which CQR was produced in vitro via modification of a single gene, allowed us to begin investigations into the relationship between pfcrt, CQR, and P. falciparum susceptibility to related antimalarials. We focused initially on amodiaquine, a chloroquine analog with the same aminoquinoline ring that differs by the presence of an aromatic ring in the side chain ( fig. S3 ). Drug assays showed that the lines harboring mutant pfcrt were slightly less susceptible to fig. S3 . The finding that pfcrt mutations conferred increased susceptibility to both quinine and mefloquine provides an intriguing contrast with the recent report that the introduction of mutations into pfmdr1 led to decreased susceptibility to quinine and increased susceptibility to mefloquine (17 7G8 showed a statistically significant difference from values observed in C2 GC03 (**P Ͻ 0.01). The chloroquine data in (A) and (G) prove a central role for pfcrt point mutations in conferring CQR to the GC03 line, although they do not rule out the possibility that other loci can contribute to this phenotype. It remains to be established whether mutant pfcrt alleles can confer CQR to multiple, genetically distinct chloroquine-sensitive lines. One hypothesis under consideration is that pfcrt confers CQR and altered susceptibility to other heme-binding antimalarials through a combination of direct effects (which may involve drug-protein interactions) and indirect effects on parasite physiological processes (which may influence drug accumulation and formation of drug-heme complexes).
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www.sciencemag.org SCIENCE VOL 298 4 OCTOBER 2002 amodiaquine (Fig. 1B) ; nonetheless, the pfcrt-modified clones remained sensitive to this drug, with IC 50 values of 22 to 36 nM. A modest degree of cross-resistance was observed between chloroquine and monodesethylamodiaquine, the primary metabolite of amodiaquine (table S2) (26 -28) . These findings are consistent with the published data on amodiaquine efficacy in areas with a high prevalence of CQR malaria (29, 30) and signal the need for close monitoring for resistance, including screening for possible additional changes in pfcrt sequence, with increased clinical use of amodiaquine. Further, these data suggest that CQR mediated by pfcrt point mutations now prevalent in endemic areas has a high degree of specificity for the chloroquine structure ( fig. S3 ). Other groups have reported that altering the chloroquine side chain length can result in a gain of efficacy against chloroquine-resistant lines (31, 32) .
Phenotypic characterization also revealed increased susceptibility (by a factor of 2 to 4) to quinine, mefloquine, and artemisinin and its metabolite dihydroartemisinin in the pfcrtmodified clones (Fig. 1 , C, E, and F) (table  S2) . These data provide direct evidence for an important role for this gene in determining parasite susceptibility to these antimalarials. Collateral hypersensitivity to these compounds is reminiscent of antimalarial susceptibility patterns observed in a Thailand study of P. falciparum field isolates (33) and is encouraging given their current clinical usage in antimalarial combination therapy regimes (34) . In comparison to C2 GC03 , the Dd2 line is more quinine resistant; however, the introduction of the Dd2 pfcrt allele (resulting in the clones C3 Dd2 and C4 Dd2 ) conferred quinine susceptibility (Fig. 1C ). This implicates pfcrt as a component of a multifactorial process that governs parasite susceptibility to these antimalarials. Upon introduction of pfcrt point mutations, the increased susceptibility to quinine was accompanied by a decrease in susceptibility to the diastereomer quinidine ( Fig. 1, C and D) .
These data, obtained in lines that were not exposed to chloroquine pressure during their selection, agree with an earlier observation on the chloroquine-selected K76I line (7, 8) and suggest a structure-specific component of PfCRT-mediated drug accumulation in the digestive vacuole. All of these compounds are believed to act, at least in part, by complexing with heme products (35, 36) . Possibly, PfCRT mutations affect accumulation by altering drug flux across the digestive vacuole membrane. Our data also document a key role for pfcrt point mutations in the mode of action of verapamil, a known CQR reversal agent (22, 25, 37, 38) that also chemosensitized the pfcrt-modified lines to quinine and quinidine ( Fig. 1, C and D) . This verapamilreversible phenotype may reflect a physical association between verapamil and mutant PfCRT and/or mutant PfCRT-mediated physiological changes that alter the activity of verapamil on heme processing and drughematin binding. Our genetic system now provides a direct means to evaluate the precise role of individual pfcrt point mutations in determining P. falciparum drug response and verapamil reversibility, via site-directed mutagenesis and introduction of mutant alleles into chloroquine-sensitive lines.
These data are consistent with the concept that the appearance of pfcrt mutant alleles in a limited number of foci was the pivotal driving force behind the genesis and spread of CQR worldwide. The structural specificity of this pfcrt-mediated resistance mechanism is underscored by the finding that pfcrt-modified clones remained susceptible to amodiaquine, promoting the use of this and related compounds that differ in their aminoquinoline side chain for the treatment of chloroquine-resistant falciparum malaria. Identification of PfCRT as the major component of CQR and an important determinant of susceptibility to other heme-binding antimalarials offers alternative strategies for targeting the hemoglobin detoxification pathway for malaria treatment and control.
Note added in proof: Wootton et al. (39) recently presented compelling evidence for rapid evolutionary sweeps of mutant pfcrt sequences throughout malaria-endemic areas, starting from a limited number of initial foci. These sweeps presumably occurred as a result of intense chloroquine pressure. These data complement and support our finding that mutant pfcrt sequences from different continents can confer CQR to chloroquine-sensitive parasites. GC03 in the second round used plasmids containing the blasticidin S-deaminase (BSD) selectable marker (41) and resulted in the C2 to C6 clones. GC03 is a chloroquine-sensitive progeny of the genetic cross between the chloroquine-resistant clone Dd2 (Indochina) and the chloroquine-sensitive clone HB3 (Honduras) (5, 6) . Dd2 and 7G8 (Brazil) represent common PfCRT haplotypes found in Asia/Africa and South America, respectively (7). K76I is a chloroquine-resistant line selected from the chloroquine-sensitive 106/1 (Sudan) clone propagated in the presence of high chloroquine concentrations, resulting in the generation of a full complement of PfCRT point mutations including the novel K76I mutation (8) . Point mutations in boldface are those previously associated with CQR (7, 8) . Abbreviations for amino acid residues: A, Ala; C, Cys; D, Asp; E, Glu; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; Q, Gln; R, Arg; S, Ser; T, Thr. Successful propagation of the malaria parasite Plasmodium falciparum within a susceptible mosquito vector is a prerequisite for the transmission of malaria. A field-based genetic analysis of the major human malaria vector, Anopheles gambiae, has revealed natural factors that reduce the transmission of P. falciparum. Differences in P. falciparum oocyst numbers between mosquito isofemale families fed on the same infected blood indicated a large genetic component affecting resistance to the parasite, and genome-wide scanning in pedigrees of wild mosquitoes detected segregating resistance alleles. The apparently high natural frequency of resistance alleles suggests that malaria parasites (or a similar pathogen) exert a significant selective pressure on vector populations.
Mosquitoes infected with malaria incur quantifiable costs in reproductive fitness for measures such as longevity, fecundity, and flight distance (1-3). In addition, mosquito immune genes respond transcriptionally to malaria parasite infection (4-6), indicating that malaria parasites are detected by mosquito immune surveillance. Inbred lines selected from mosquito colonies can inhibit parasite development through at least two distinct mechanisms: melanotic encapsulation and intracellular lysis (7, 8) . Therefore, selective pressure by parasite infection could drive the natural selection of resistance mechanisms in mosquitoes. However, previous studies of resistance used laboratory strains of mosquitoes and malaria parasites, which are known to display biological aberrations in comparison to natural populations (9) (10) (11) , and thus the relevance of these studies to natural malaria transmission may be questioned. Malaria resistance mechanisms and their significance for the biology of malaria transmission have not been examined previously in natural field populations of vectors. For study of the vector-parasite interaction using field populations, standard genetic techniques that require the creation of inbred or isogenic lines were not applicable. However, the large number of progeny produced by single wild females permitted a novel study design based on isofemale pedigrees, which is quite distinct from designs previously used in human and animal genetics ( fig.  S1 ). In nature, A. gambiae females mate only once (12) , and the stored sperm is used to fertilize successive egg batches that mature when the female feeds on blood. We captured pre-mated blood-fed females resting in village dwellings in Bancoumana, Mali (West Africa); allowed them to oviposit in an environmentally controlled chamber; and then raised their respective progeny in the environmental chamber (13) . We used the isofemale families at either the F 1 or the F 2 stage (the latter produced by mass mating of F 1 mosquitoes). All females of a family were challenged with malaria parasites by being fed on blood from the same P. falciparum gametocyte carrier (14) . Unfed mosquitoes were removed (15) . At 8 days after infection, the progeny were dissected, and the surviving oocyst-stage parasites were counted in each midgut. The number of oocysts per mosquito constituted the quantitative infection phenotype.
We investigated the genetic dependence of mosquito resistance to malaria infection in two stages. First, in a familiality study, we compared parasite infection levels between mosquito families that were each generated by a different founding pair of wild mosquitoes. The goal was to measure interfamily differences in infection distributions, and therefore only phenotype measurements were used. Groups of three F 1 families were reared together in an environmental chamber and were fed simultaneously on blood from a Parasite transfection. P. falciparum parasite lines were propagated in human red blood cells (RBC) in RPMI medium supplemented with 0.5% Albumax and were electroporated with purified plasmid DNA, as described (S1). Transformed parasites were selected using 5 nM WR99210 and 5 µM Blasticidin HCl (Invitrogen) to select for the human dihydrofolate reductase (hDHFR) and blasticidin S-deaminase (BSD) selectable markers, respectively (S1, S2). Episomal transformation was quantified by plasmid rescue (S3).
Nucleic acid and protein analysis. P. falciparum genomic DNA was purified using the NaClO 4 method (S3, S4) . Total RNA was isolated using the Qiagen RNeasy kit and residual DNA contamination was removed by DNase I treatment. cDNA was synthesized from total RNA using oligo (dT) priming and Superscript-II reverse transcriptase (Invitrogen). Tests for genomic DNA contamination were performed in parallel with mock cDNA reaction samples lacking reverse transcriptase.
Southern hybridizations were performed with hexamer-primed (Fig. S2B) . A schematic representation of the pfcrt locus in the recombinant and control lines is shown in Fig. S1 .
Protein samples were prepared from parasites (enriched in late ring and early trophozoite stages) that had been saponin-lysed, washed with 1 × PBS and denatured in Laemmli buffer. Protein from 5.0 x 10 6 parasites was loaded per well, electrophoresed on a 10% SDS-PAGE gel, and electroblotted onto PVDF membranes (Bio-Rad). Membranes were probed with affinity-purified rabbit anti-PfCRT antibody (diluted 1:200) (S5), followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG (diluted 1:25,0000; Amersham Biosciences) and enhanced chemiluminescence detection. Protein loadings were normalized by four pilot gel migration and transfer assays involving detection of total protein by Coomassie blue staining of parallel gels and quantitation analysis of Western blots probed with rabbit polyclonal anti-STARP Sidhu et al.
-pfcrt and CQR -Supplement -2 antibody as an independent loading control (S6). Densitometric analysis of autoradiograph data was performed using NIH Image v1.6.2 (http://rsb.info.nih.gov/nih-image/). DNA constructs, mutagenesis and luciferase assays. pfcrt modular fragments were assembled from three contiguous sequences. The first sequence, denoted ∆1 (corresponding to nucleotides 23553-23757 of the GenBank accession number AF030694), spanned the middle of exon 1 to the intron 1/exon 2 junction. This was PCR amplified as a 229 bp fragment from Dd2 genomic DNA using the primers 5'-caagcggccgcTGAGAATTAGATAATTTAGTACAAGAA-GGAA (Not I site underlined, 5' in-frame stop codon in boldface) and 5'-cacctaggCGTGAGCCATCTGTTAAGGTC (Avr II restriction site underlined). This fragment was subcloned into pCR2.1 (Invitrogen) and the Sal I site in intron 1 was removed by replacing the internal Sal I + Avr II fragment with a double-stranded adaptor made by annealing the primers 5'-TCGAGCTTAACAGATGGCTCACGC and 5'-CTAGGCGTGAGCCATCTGTTAAGC (point mutation leading to loss of Sal I site is underlined).
The second sequence, denoted exons 2-13 (corresponding to nucleotides 23764-26533), was PCR amplified as a 1162 bp fragment from oligo (dT) primed cDNA of Dd2, 7G8 and GC03 using the primers 5'-acgcctaggTGGAGGTTCTTGTCTTGGTA and 5'-tgagtcgacGTTGGTTAA-TTCTCCTTC (Avr II and Sal I restriction sites underlined). The K76I insert was generated from the Dd2 exons 2-13 fragment following site-directed mutagenesis (Quikchange, Stratagene) with the primers 5'-GTGTATGTGTAATTGAAATAATTTTTGCTAAAAGAAC and 5'-GTTCTTTTAGCAAAAATTATTTCAATTACACATACAC (mutagenized codon 76 position underlined).
The third sequence, denoted Pf3' (corresponding to nucleotides 26540-27590) was PCR amplified as a 1069 bp fragment from the Dd2 pfcrt 3' UTR region with the primers 5'-aacgtcgacTCAATTATTACACAATAAAAATATATC (Sal I site underlined, stop codon in boldface) and 5'-gaaggatccTAACTAAACTTGAAATAAGTGGCG (BamH I restriction site underlined). Exons 2-13 and Pf3' products were cloned into the pGEM-T vector (Promega). All inserts were sequenced on both strands to identify error-free clones. Inserts ∆1, exons 2-13 and Pf3' were ligated together using their cohesive ends and subcloned as a 2431 bp Not I + BamH I fragment into the 5.7 kb plasmids pHDWT (S1) and pCBM-BSD (S2). These plasmids express hDHFR and BSD under the control of the P. falciparum hrp3 5' UTR and hrp2 3' UTR regulatory elements.
To increase the frequency of single-site crossover events at the 5' end of the pfcrt fragment upstream of codons 72-76, we replaced the 1.0 kb Pf3' fragment with a 0.7 kb fragment, denoted Py3', from the 3' UTR region of the P. yoelii rodent ortholog pycg10 (A. B. S. Sidhu and D. Fidock, unpublished data; S7). Py3' was amplified using the primers 5'-acgtcgac-TCAATTATTACACAATAAATATTTTTTTTAAATGCCAC (HPLC-purified, Sal I site underlined; boldface letters represent pfcrt exon 13 sequence up to the stop codon, remainder is from the pycg10 locus) and 5'-caggatccTATTTCAAAAATCTTAGCATAAGG (BamH I site underlined). This fragment was cloned into all pBSD-based constructs. Both the Pf3' and Py3' fragments were confirmed to be functional in transient transfection luciferase assays using pHLH-1- S8) . Controlled duplicate experiments performed three times by DNA preloading of uninfected RBC (S9) demonstrated luciferase activities averaging 59% of those obtained with pHLH-1, with no significant differences in activity between Pf3' and Py3' (data not shown). Electroporations were performed on days zero and two, and parasites were harvested on day three by saponin lysis. Luciferase activities were measured in 1X luciferase reporter lysis buffer (Promega) on an autoinjector luminometer (Autolumat LB953, EG&G Berthold, Perkin Elmer).
PCR-based detection of allelic exchange events and parasite cloning. Parasite lines episomally transformed with the pfcrt allelic exchange constructs were PCR screened every month for integration events occurring as a result of homologous recombination and single-site crossover. Because all three P. falciparum fragments (pfcrt, hrp3 and hrp2) in the transformation plasmids represented potential sites of integration, these were separately screened for integration. pfcrt integration was tested using PCR primer combinations listed in Table S1 (separate file). The presence of human dhfr was confirmed using the primers 5'-ATGCATGGTTCGCTAAACTGCATCG and 5'-AAGCTTAATCATTCTTC-TCATATACTTC (producing a 0.57 kb fragment). The primer combinations 5'-TAATACGACTCACTATAGGG + 5'-AACAAGTTATTGTTAAATTCGGAG and 5'-CACGAAGCCGCCACACATTGCC + CAAAGGAGCAAACAATTTTGTC were used to screen for integration into hrp3 (resulting in a 2.19 kb band) and hrp2 (producing a 1.02 kb band) respectively.
Mutation-specific PCR screening for exchange of point mutations in codons 72-76 was performed using the primers 5'-GTTCTTTTAGCAAAAATTGTTTCA (Dd2) or 5'-GTTCTTTTAGCAAAAATTTTATTC (GC03), combined with the ubiquitous primer 5'-AATTTCTTACATATAACAAAATGAAATTCGCAAGT. PCR products were sequenced using internal primers. In some instances, strategies to detect rare integration events were facilitated by the loss of a Sal I site in intron 1 and the introduction of novel Avr II and Sal I sites into exons 2 and 13, respectively (none of these changes altered the coding sequence). The proportion in each transformed line of parasites that had undergone pfcrt allelic exchange was estimated by comparing yields of recombinant and wild-type PCR products obtained with several genomic DNA dilutions and primer pairs. Parasites were cloned by limiting dilution (up to 3 series, with a maximum first series of 10 3 infected RBC per well and a last series at 0.25 infected RBC per well) in 96-well tissue culture plates. Clones were detected using the P. falciparum lactate dehydrogenase-specific Malstat™ assay (S10).
In vitro antimalarial drug assays. Table S2 (see separate file) and Fig. S3 (see below) .
Chloroquine accumulation analysis. P. falciparum parasites were sorbitol-synchronized and assayed at 2-8% parasitemia, 75-85% early to mid-stage trophozoites and 2-3% hematocrit. [
3 H]-labeled chloroquine (specific activity 5 Ci/mmol, American Radiolabeled Chemicals) was added to duplicate samples (each at 0.3 ml of culture) at a final concentration of 30 nM. This value is close to the IC 50 value of the CQS clones (Table S2 ). Assays were carried out in RPMI medium (containing NaHCO 3 ) for up to 60 minutes at 37°C in 24-well plates placed in humid chambers gassed with 5% O 2 / 5% CO 2 / 90% N 2 . Samples were then centrifuged through silicon oil (d = 1.050, Aldrich) to separate the RBC pellet from unincorporated label, and the pellets and supernatants processed as described (S12-S14). Control samples included uninfected RBC and infected RBC in which the Additional constructs that were used included pBSD-crt-Dd2
Pf3'
, pBSD-crt-K76I
and pBSDcrt-7G8 Py3'
. Pf3' and Py3' constructs were 8.1 kb and 7.7 kb respectively. These constructs contained pfcrt sequences from the CQR lines Dd2 (Indochina), K76I (of Sudanese origin) and 7G8 (Brazil). Superscripts refer to the origin of the 3'UTR (Pf3', 1.1 kb fragment from pfcrt; Py3', 0.7 kb fragment from pycg10). (C) C3 Dd2 and C4 Dd2 differ in their 3' UTR. C5 K76I and C6 7G8 (not shown) differ in the pfcrt coding sequence, which came from K76I and 7G8
respectively and which resulted in the expression of a distinct PfCRT haplotype. C2 GC03 was generated from C1 GC03 transformed with pBSD-crt-Dd2
Py3'
. In C2
GC03
, recombination occurred in the contiguous hrp3 / pBluescript (pBS) region downstream of the functional pfcrt allele. This did not alter the pfcrt coding sequence and served as a critical internal control for phenotypic analysis. PfCRT haplotypes and primer details are listed in Tables 1 and S2 respectively. All sequences are drawn to scale except for pBS and the hDHFR and BSD selectable markers (all 3.0 kb). C, Cla I; S, Sal I; Pf3' and Py3' are from the 3' UTR regions of pfcrt and pycg10, respectively; and represent pfcrt sequences from the CQR line Dd2 and the CQS lines GC03 and C1
, respectively. (Fig. S1 , data not shown). Allelic replacement was confirmed by sequence analysis of PCR products (data not shown). Primer sequences and band sizes are listed in Table S1 (see separate file). (E) Western blot analysis revealed expression of full-length PfCRT in control and recombinant clones. Fig. S3 . Structure of antimalarial drugs and active metabolites tested against pfcrt-modified clones. Quinine, quinidine, and mefloquine (all quinoline methanols) share the aminoquinoline ring found in chloroquine and its side-chain analog amodiaquine, whereas this ring is absent in artemisinin (a sesquiterpene peroxide). 
